TY - JOUR
T1 - Supramolecular encapsulation of nanocrystalline Schiff bases into β-cyclodextrin for multifold enrichment of bio-potency
AU - Mahato, Rajani Kanta
AU - Debnath, Ananya
AU - Das, Ajit
AU - Sarkar, Debanjan
AU - Bhattacharyya, Sankar
AU - Biswas, Bhaskar
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/9/1
Y1 - 2022/9/1
N2 - We report the solvent-free green synthesis of two Schiff bases, (E)-2-((2-hydroxy-3-methoxybenzylidene)amino)-4-methylphenol (SL1) and (E)-2-((2-hydroxybenzylidene) amino)-4-methylphenol (SL2), and their inclusion complexes with β-cyclodextrin (β-CD). The encapsulation phenomenon, structural characteristics and hydrolytic stabilities of the SL1, SL2 and their inclusion complexes are determined with a suite of spectroscopic, analytical and crystallographic analyses. Dose and time-dependent cytotoxicity study of SL1-β-CD and SL2-β-CD against two breast cancer cell lines, Michigan Cancer Foundation-7 (MCF-7) and metastatic mammary adenocarcinoma1 (MDA-MB-231), exhibit excellent inhibitory activity with significant non-cytotoxic concentrations and ensure a multifold elevation of bio-potency than the parent Schiff base compounds. The Annexin-V assay determines the efficacy of these inclusion complexes to trigger apoptosis, suggesting that SL2-β-CD possesses better efficacy as an anti-cancer drug. To the best of our knowledge, we, for the first time, report the inclusion of nanocrystalline Schiff bases into β-CD for multifold enrichment of bio-potency.
AB - We report the solvent-free green synthesis of two Schiff bases, (E)-2-((2-hydroxy-3-methoxybenzylidene)amino)-4-methylphenol (SL1) and (E)-2-((2-hydroxybenzylidene) amino)-4-methylphenol (SL2), and their inclusion complexes with β-cyclodextrin (β-CD). The encapsulation phenomenon, structural characteristics and hydrolytic stabilities of the SL1, SL2 and their inclusion complexes are determined with a suite of spectroscopic, analytical and crystallographic analyses. Dose and time-dependent cytotoxicity study of SL1-β-CD and SL2-β-CD against two breast cancer cell lines, Michigan Cancer Foundation-7 (MCF-7) and metastatic mammary adenocarcinoma1 (MDA-MB-231), exhibit excellent inhibitory activity with significant non-cytotoxic concentrations and ensure a multifold elevation of bio-potency than the parent Schiff base compounds. The Annexin-V assay determines the efficacy of these inclusion complexes to trigger apoptosis, suggesting that SL2-β-CD possesses better efficacy as an anti-cancer drug. To the best of our knowledge, we, for the first time, report the inclusion of nanocrystalline Schiff bases into β-CD for multifold enrichment of bio-potency.
KW - Antiproliferative activity
KW - Encapsulation
KW - Nano-crystal
KW - Schiff base
KW - X-ray crystallography
KW - β-Cyclodextrin
UR - http://www.scopus.com/inward/record.url?scp=85130404041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130404041&partnerID=8YFLogxK
U2 - 10.1016/j.carbpol.2022.119614
DO - 10.1016/j.carbpol.2022.119614
M3 - Article
C2 - 35698411
AN - SCOPUS:85130404041
SN - 0144-8617
VL - 291
JO - Carbohydrate Polymers
JF - Carbohydrate Polymers
M1 - 119614
ER -